source
- Analysts deem AstraZeneca-BMS merger unlikely despite market buzzAnalysts say that talks between AstraZeneca and Bristol Myers Squibb are unlikely to result in a merger because the two companies have overlapping product lines that would attract heavy antitrust s…
- Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cutsAngus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discuss…